Development of fish tests for endocrine disruptors
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 37886176X | ||
| 003 | CHVBK | ||
| 005 | 20180305123348.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20030101xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1351/pac200375112343 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1351/pac200375112343 | ||
| 245 | 0 | 0 | |a Development of fish tests for endocrine disruptors |h [Elektronische Daten] |c [T. H. Hutchinson, H. Yokota, S. Hagino, K. Ozato] |
| 520 | 3 | |a International concern over endocrine active substances (EASs) has led to intensive research programmes to establish fish reproductive and developmental toxicity tests for use in environmental (ecological) risk assessment. This chapter gives an overview of key themes of in vivo ecotoxicology research, including fish screening assays, partial life-cycle tests (the draft OECD fish reproduction test and the new fish development test) and fish full life-cycle tests. In the context of the OECD test guidelines program, fish species of primary interest include fathead minnow, medaka and zebrafish, while guppy, rainbow trout, sheepshead minnow, and three-spined stickleback are also of scientific importance. Critical factors for evaluation include baseline reproductive biology and definition of EAS sensitive life-stages. For regulatory applications, a critical review of existing fish EAS data suggests that apical adverse effect endpoints, namely development, growth and reproduction (e.g., fecundity, fertilization rates, and hatching success) should be used to derive predicted no-effect concentrations (PNECs) for the environmental risk assessment of EASs. In support of these apical adverse effect endpoints, biomarker responses (e.g., vitellogenin, gonadal-somatic index, and gonad histopathology) should be used to provide mechanistic data, compare species (e.g., cyprinids vs. salmonids), and allow extrapolation between laboratory and field studies. | |
| 540 | |a © 2013 Walter de Gruyter GmbH, Berlin/Boston | ||
| 700 | 1 | |a Hutchinson |D T. H. |u AstraZeneca Global Safety Health &Environment, Brixham Environmental Laboratory, Brixham, Devon TQ5 8BA, UK; Kurume Laboratory, Chemicals Evaluation and Research Institute (CERI), Japan; Sumika Technoservice Corporation, Takarazuka-city, Japan; Nagoya University Bioscience Center, Nagoya, Japan |4 aut | |
| 700 | 1 | |a Yokota |D H. |u AstraZeneca Global Safety Health &Environment, Brixham Environmental Laboratory, Brixham, Devon TQ5 8BA, UK; Kurume Laboratory, Chemicals Evaluation and Research Institute (CERI), Japan; Sumika Technoservice Corporation, Takarazuka-city, Japan; Nagoya University Bioscience Center, Nagoya, Japan |4 aut | |
| 700 | 1 | |a Hagino |D S. |u AstraZeneca Global Safety Health &Environment, Brixham Environmental Laboratory, Brixham, Devon TQ5 8BA, UK; Kurume Laboratory, Chemicals Evaluation and Research Institute (CERI), Japan; Sumika Technoservice Corporation, Takarazuka-city, Japan; Nagoya University Bioscience Center, Nagoya, Japan |4 aut | |
| 700 | 1 | |a Ozato |D K. |u AstraZeneca Global Safety Health &Environment, Brixham Environmental Laboratory, Brixham, Devon TQ5 8BA, UK; Kurume Laboratory, Chemicals Evaluation and Research Institute (CERI), Japan; Sumika Technoservice Corporation, Takarazuka-city, Japan; Nagoya University Bioscience Center, Nagoya, Japan |4 aut | |
| 773 | 0 | |t Pure and Applied Chemistry |d De Gruyter |g 75/11-12(2003-01-01), 2343-2353 |x 0033-4545 |q 75:11-12<2343 |1 2003 |2 75 |o pac | |
| 856 | 4 | 0 | |u https://doi.org/10.1351/pac200375112343 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1351/pac200375112343 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hutchinson |D T. H. |u AstraZeneca Global Safety Health &Environment, Brixham Environmental Laboratory, Brixham, Devon TQ5 8BA, UK; Kurume Laboratory, Chemicals Evaluation and Research Institute (CERI), Japan; Sumika Technoservice Corporation, Takarazuka-city, Japan; Nagoya University Bioscience Center, Nagoya, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yokota |D H. |u AstraZeneca Global Safety Health &Environment, Brixham Environmental Laboratory, Brixham, Devon TQ5 8BA, UK; Kurume Laboratory, Chemicals Evaluation and Research Institute (CERI), Japan; Sumika Technoservice Corporation, Takarazuka-city, Japan; Nagoya University Bioscience Center, Nagoya, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hagino |D S. |u AstraZeneca Global Safety Health &Environment, Brixham Environmental Laboratory, Brixham, Devon TQ5 8BA, UK; Kurume Laboratory, Chemicals Evaluation and Research Institute (CERI), Japan; Sumika Technoservice Corporation, Takarazuka-city, Japan; Nagoya University Bioscience Center, Nagoya, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ozato |D K. |u AstraZeneca Global Safety Health &Environment, Brixham Environmental Laboratory, Brixham, Devon TQ5 8BA, UK; Kurume Laboratory, Chemicals Evaluation and Research Institute (CERI), Japan; Sumika Technoservice Corporation, Takarazuka-city, Japan; Nagoya University Bioscience Center, Nagoya, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Pure and Applied Chemistry |d De Gruyter |g 75/11-12(2003-01-01), 2343-2353 |x 0033-4545 |q 75:11-12<2343 |1 2003 |2 75 |o pac | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||